Cytokinetics closed the quarter as a different company than the one that opened it. MYQORZO, the cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy, began its first commercial sales in the last week of January 2026, and the interim report carries the first net product revenue line the company has ever printed. The central debate is not whether MYQORZO is a real drug. The question is whether a launch that produced $25.3 million in one full quarter can scale fast enough to outrun a royalty burden that now accrues interest at an imputed rate above 26 percent and a capital structure built to fund a drug that has not yet been approved. The market is pricing a commercial inflection into a stock with no trailing earnings. The filing shows the inflection starting, but it also shows the price of the financing that got the company here. What could make the current price wrong is a ramp that stalls in the second half while the royalty and interest obligations keep compounding.
Total revenue for the second quarter sat at $28.6 million. The operating expense stack was $207.8 million. Cash and marketable securities of $1.7 billion sit against total borrowings of $1.31 billion. The first product is real, the balance sheet is loaded, and the second product that much of the valuation implicitly depends on has not reported its pivotal trial.